Harvard Bioscience announced that CEO John Duke and CFO Mark Frost will participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum on November 11, 2026. John Duke will present on a panel about emerging tools for research and biopharma use cases. This event highlights Harvard Bioscience's role in advancing life science technologies and connects them with key industry stakeholders. The participation may boost the company's visibility and partnerships in the medtech sector.
Harvard Bioscience's participation in the Canaccord Genuity MedTech Forum is presented here with a snapshot of the health sector on Pluang as of Nov 04, 2026 18:41 WIB. Among 150 priced US health stocks, 118 rose and 24 fell today. Notably, Novo Nordisk A/S (NVO) traded at USD 42.33 with a 5.32% increase and a typical hold time of 118 days, contrasting with Inovio Pharmaceuticals Inc (INO) at USD 1.76, up 6.02%, but with a shorter hold time of 41 days and a Pluang order activity slightly favoring selling (53% Sell / 47% Buy). Heron Therapeutics Inc (HRTX) also rose 5.37% to USD 0.30, with a hold time of 38 days and stronger buying interest (34% Sell / 66% Buy).
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
Dimensional Fund Advisors Ltd. has disclosed an interest in 1,516,595 ordinary shares of DCC Energy plc, representing 1.78% of the company's shares as of November 3, 2026. The disclosure follows regulatory requirements under the Irish Takeover Panel ...
Transocean's Q3 results missed revenue and EPS expectations, causing a 5.3% share drop. However, the company remains a buy due to a growing backlog of $12.7 billion combined with Valaris and reduced net debt of $4.23 billion. The Valaris merger is ex...
